I Opening Remarks

Joint Committee (JC) Chairperson Brian Zamora welcomed everyone and called the meeting to order. Rachel Brooker read the antitrust statement and completed roll call.

II Review of Agenda

Zamora asked for any additions to the agenda but none were voiced.

Motion: Michael McGuffin motioned to accept the proposed agenda.
Seconded: Darryl Sullivan
Objections: None
Abstentions: None
Vote by verbal affirmation: None opposed.
Motion passed.

III Review of 2019 Meeting Summary

Zamora asked if there were any additions or corrections to the 2019 Joint Committee on Dietary Supplements meeting summary but none were voiced.

Motion: Sullivan motioned to approve the 2019 meeting summary.
Seconded: Mike Bradley
Objections: None
Abstentions: McGuffin
Vote by verbal affirmation: None opposed.
Motion passed.

IV Membership Review

Brooker informed the group that JC with 8 Industry, 7 Users, and 6 Public Health (PH) members. This group is deficient in PH stakeholders, and R. Brooker requested that anyone who knows of a PH representative that would be interested in joining to please contact her after the meeting.

V Old Issues

A. DS-2016-8 Probiotic Viability 173166

Discussion: Boguslawa Kocot stated that she does not have any updates due to reorganization within her department. She added that the difficulty with this issue paper is that there is no universal approach for probiotics. Kocot noted that lot of laboratories are struggling on a standardized approach.
B. DS-2018-1 Enzymes 173i75

Discussion: Alaina Perkins informed the JC that this issue paper was put on hold for the time being.

C. DS-2018-2 Protein 173i76

Discussion: Brooker noted that after the revision 2 ballot had negative comments the issue proponent, Sylvia Laman, officially withdrew the issue paper. Brooker then asked if there were any objections to Laman’s withdrawal. Laman explained that this issue paper was originally written not to change the intent of the standard but to add clarity to the current language. The negative comments from the ballots it seemed that the proposed revisions added more confusion than clarity and that is why it was withdrawn. The JC agreed to this.

D. DS-2018-3 Formulation 173i77

Discussion: Katie Fillinger stated that this was still being worked on internally and there is no new draft to show the JC.

E. DS-2018-8 Ephedrine Alkaloids 173i82

Discussion: Michael McGuffin stated that he went back to each commenter and asked them if the new draft would fix their comment.

Fillinger stated that the manufacturing statements should be in section 8 since section 5 is about testing. McGuffin suggested that she open a separate issue paper to address that.

After some discussion the JC agreed on the language below.

5.3.4.3 Ephedrine alkaloids

Except as noted in the following paragraphs, dietary ingredients and finished products that consist of or include Ephedra spp. and are marketed in the United States shall be analytically confirmed to be free of ephedrine alkaloids at a limit of detection of 0.1 ppm or lower.

Some countries permit the marketing of finished products that contain ephedrine alkaloid containing species belonging to the genus Ephedra but regulate the maximum amount of ephedrine alkaloids in the product. Such products marketed in those countries shall be analytically confirmed to contain no more than the permitted amount of ephedrine alkaloids.

E. nevadensis and E. viridis do not contain ephedrine alkaloids at physiologically relevant concentrations. Ingredients and finished products that consist of or are derived from these botanicals, and that are not manufactured in a way that concentrates or adds ephedrine alkaloids, do not require analytical confirmation for the presence of ephedrine alkaloids. Examples of such ingredients and products include tablets or capsules containing ground raw material or extracts made using water, ethanol, or other food-grade solvents and using no steps intended to concentrate alkaloids disproportionately to other constituents of these species.
Compliance with this Section shall be verified in accordance with Section 7.4.

**Motion:** Betz moved to ballot the language above.
**Seconded:** Wendy Applequist
**Objections:** None
**Abstentions:** None
**Vote by verbal affirmation:** None apposed.
Motion passed

**F. DS-2018-11 Section 7.1 SierraSil 173i85**

**Discussion:** Brooker informed the JC that at the 2019 meeting there was a motion to create a TG to discuss the data but no one volunteered for that TG. She noted that she reached out to SierraSil representatives and they stated that they wanted to wait until some NSF toxicologists to go through the data first. She did ask if there was anyone who wanted to speak on this but no one spoke up.

**VII New Issues**

**A. DS-2020-1 Tables 5.1, 5.2, and 5.4 173i91**

**Discussion:** Kocot presented that this issue paper proposes changing the order of the table for better alignment. Applequist suggested creating a fourth line for ‘other’. Brooker also called the group’s attention to the ‘and/or’ statement and explained that ANSI is getting stricter on this language and all ‘and/or’ statements had to be removed. After some discussion it was decided to create a TG to reword all ‘and/or’ statements. One attendee did question that if there are products with both which limit is observed. Harvey confirmed that the least strict limit is used when it is a mixture. Harvey also suggested that there needs to be a line for animal derived ingredients.

Eisner proposed that thought needs to be given to manufacturers with a kill step. Betz added that some pathogens when killed put off some toxins so there needs to be some NSF experts weighing in on this topic. It was suggested to get a thermal processor to participate. Eisner mentioned that there may be some at Eurofins.

A few attendees were confused on which sections are for the third party certifier to compete and which are for the manufacturers. Fillinger offered to create an issue paper to make an intro to various sections to clarify this.

**Motion:** Betz motioned to create a TG to discuss this issue paper.
**Seconded:** Michael Bradley
**Objections:** None
**Abstentions:** None
**Vote by verbal affirmation:** None apposed.
Motion passed

**B. DS-2020-2 Section 7.3.9 Pseudomonas 173i92**

**Discussion:** Kocot explained that this issue paper is to ensure consistency within the standard. Eisner suggested to ballot for the sake of consistency but as a separate thing to review this to make sure it is the correct number. She motioned to create a micro TG to review section 7.
Motion: Eisner moved to ballot and create a micro TG to review section 7.
Seconded: McGuffin
Objections: None
Abstentions: Betz
Vote by verbal affirmation: None apposed.
Motion passed

C. DS-2020-3 Section 7.3.7.2 173I93

Discussion: Kocot explained that this issue paper was derived from lab experience and discussions with other labs. The only suggested change to this issue paper is to change “i.e.” to “e.g.”

Motion: Betz motioned to ballot with changing “i.e.” to “e.g.”
Seconded: Eisner
Objections: None
Abstentions: None
Vote by verbal affirmation: None apposed.
Motion passed

D. DS-2020-4 Section 7.3.2 173I94

Discussion: Kocot presented that this was a simple correction to the language.

Motion: Betz motioned to go to ballot.
Seconded: McGuffin
Objections: None
Abstentions: None
Vote by verbal affirmation: None apposed.
Motion passed

E. DS-2020-5 Section 5.3.3 173I95

Discussion: Kocot stated that this is a correction because if something is exactly 50% it doesn’t fall into a category since the categories are below or above 50%.

Motion: Betz motioned to go to ballot.
Seconded: Bradley
Objections: None
Abstentions: None
Vote by verbal affirmation: None apposed.
Motion passed

VIII New Business & Next Meeting

A. New Business

Discussion: Brooker did an impromptu presentation on how to properly write an issue paper. She explained that it is very important to follow the instructions on the issue paper for order of things as well as the editing. The first important piece of information on the very top of the paper is the standard or standards that are impacted by this issue paper. The first section on the issue paper is the ‘Background’ section. Brooker explained that this is where you justify and give evidence for your suggested change. She reminded everyone that this section should not have any of the actual suggested change and that anything in this section will not make it into the actual ballot and therefore the standard. She gave the example from a couple of years ago that an equation was placed in this section that was
supposed to be in the standard, but it was not added because it was not in the 'Recommendation' section. Brooker then stated that the 'Recommendation' section is where you place what you want changed in the standard. She noted that it was very important to follow the instructions on the issue paper for editing which is to highlight, in grey only, any suggested new text and to strikethrough or underline any suggested text to delete. She added that it is her personal preference to use strikethrough since it is more obvious. She explained that these are ANSI's only approved editing practices. She also added that while she cannot give anyone, including NSF staff, a full Word version of the standard you can reach out to her and ask for a specific section of the standard in Word if you are creating an issue paper. It was requested that she write up a full presentation to give out to the whole JC on this topic.

B. 2021 meeting

Discussion: Brooker reminded the group that there is a standing date for the meeting to be held from 8 am to 12 pm the day before SupplySide West floor opens in the general location of SupplySide West. This year will hopefully be an anomaly and the JC will be able to meet in person again in 2021. While the general date still stands the exact date and location cannot be announced at this time due to the ongoing pandemic.

IX Adjournment

Motion: McGuffin motioned to adjourn the meeting.
Seconded: Jost
Objections: None
Abstentions: None
Vote by verbal affirmation: None apposed.
Motion Passed.
## Member Attendance

<table>
<thead>
<tr>
<th>Name</th>
<th>Organization</th>
<th>Affiliation</th>
<th>Role</th>
</tr>
</thead>
<tbody>
<tr>
<td>Brian Zamora</td>
<td>County of San Mateo</td>
<td>General Interest</td>
<td>Joint Committee Chair</td>
</tr>
<tr>
<td>Staci Eisner</td>
<td>Cortex Scientific Botanicals</td>
<td>Industry</td>
<td>Vice chair</td>
</tr>
<tr>
<td>Rachel Brooker</td>
<td>NSF International</td>
<td>General Interest</td>
<td>Secretariat</td>
</tr>
<tr>
<td>Wendy Applequist</td>
<td>Missouri Botanical Garden</td>
<td>Public Health / Regulatory</td>
<td>Member</td>
</tr>
<tr>
<td>Gisele Atkinson</td>
<td>Naturelo</td>
<td>Industry</td>
<td>Member</td>
</tr>
<tr>
<td>Joseph Betz</td>
<td>National Institutes of Health (NIH)</td>
<td>Public Health / Regulatory</td>
<td>Member</td>
</tr>
<tr>
<td>Michael Bradley</td>
<td>GNC</td>
<td>Industry</td>
<td>Member</td>
</tr>
<tr>
<td>Martin Charron</td>
<td>Health Canada</td>
<td>Public Health / Regulatory</td>
<td>Member</td>
</tr>
<tr>
<td>Steven Dentali</td>
<td>Dentali Botanical Sciences</td>
<td>Industry</td>
<td>Member</td>
</tr>
<tr>
<td>Mike Harvey</td>
<td>NSF International</td>
<td>User</td>
<td>Member</td>
</tr>
<tr>
<td>Mark Jost</td>
<td>Gemini Pharmaceuticals, Inc</td>
<td>Industry</td>
<td>Member</td>
</tr>
<tr>
<td>Michael McGuffin</td>
<td>American Herbal Products Association (AHPA)</td>
<td>Industry</td>
<td>Member</td>
</tr>
<tr>
<td>Harry Rice</td>
<td>GOED</td>
<td>Industry</td>
<td>Member</td>
</tr>
<tr>
<td>Kate Rimmer</td>
<td>National Institute of Standards and Technology</td>
<td>Public Health / Regulatory</td>
<td>Member</td>
</tr>
<tr>
<td>Darryl Sullivan</td>
<td>Eurofins</td>
<td>User</td>
<td>Member</td>
</tr>
</tbody>
</table>